http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2384420-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9237fdf6dca9ac365fc5166858e7862 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-34 |
| filingDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fef00e7c073959694bd1b1656d6d794d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14bb1c8fec3fd6cb75167e6c7bfb543f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4863f403a4999a16447fa1d7d5094192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ace2eca49463ace92aa0efc2fca67a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30cda4bf02ded49fda81331ac9176ae0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be80dafd17f5193f67dedc1143c2a9f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e6c5d1ec80fb65949cf33054548a6f |
| publicationDate | 2012-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2384420-T3 |
| titleOfInvention | Antitumor compounds |
| abstract | A compound of general formula I in which Y is selected from -CHRay-, -CHRay-CHRby-, -CRay> = CRby-, -C≡C-, -CHRay-CHRby-CHRcy-, -CHRay-CRby> = CRcy - and -CHRay-C≡C-; each Ray, Rby, and Rcy is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; each R1, R2, R3, R4, and R5 is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; R6 is selected from NR8R9, and OR10; W is selected from O and NR7; R7 is selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl, or R7 and R5 together with the corresponding N atom and the C atom to which they are attached can form a substituted or non-substituted heterocyclic group substituted; R8 is selected from hydrogen, CORa, COORa, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenyl; R10 is selected from hydrogen, substituted C2-C12 alkenyl or unsubstituted, and substituted or substituted C2-C12 alkynyl; each dotted line represents an optional additional bond provided that one or more additional links are present, but when there is a triple bond between the C atoms to which they are attached R1 and R2, R1 and R2 are absent, and when there is a triple bond between the C atoms to which R3 and R4 are attached, R3 and R4 are absent; R9 is selected from hydrogen, CORa, COORa, substituted C2-C12 alkenyl or unsubstituted, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkeninyl; each group R11, R12, R13, R14, and R15 is independently selected from hydrogen, halogen, ORa, CORa, COORa, OCORa, OCO ORa, OCONRaRb, CONRaRb, OS (O) Ra, OSO2Ra, OP (O) (Ra) ORb, OSiRaRbRc, NRaRb, NRaCORb, NRaCON-RaRb, NRaS (O) Rb, NRaSO2Rb, NRaC (> = NRa) NRaRb, NRaRb, NRaRb , S (O) Ra, SO2Ra, S (O) NRaRb, SO2NRaRb, S (O) ORa, SO2ORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or substituted C2-C12 alkynyl not substituted; each Ra, Rb, and Rc is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or substituted aryl and substituted or unsubstituted heterocyclic group replaced; or a pharmaceutically acceptable salt, western stereoisomer thereof. |
| priorityDate | 2007-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 314.